London Daily

Focus on the big picture.
Friday, Aug 22, 2025

AstraZeneca's logo is reflected in a drop on a syringe needle in this illustration

Britain to become first country to trial AstraZeneca coronavirus antibody treatment

New antibody combination aims to help people with weakened immune systems
A new coronavirus antibody treatment developed by pharmaceutical giant AstraZeneca will begin clinical trials for the first time in the UK.

A volunteer from Wakefield, West Yorkshire, will become the first person in the world to receive the company’s new “antibody cocktail”, which is aimed at people with a weakened immune system who cannot be vaccinated.

The clinical trial programme will test whether the treatment will prevent Covid-19 for up to a year. It will evaluate the safety and effectiveness of a combination of two long-acting monoclonal antibodies, which are man-made proteins that act like natural human antibodies in the immune system.

5,000 volunteers will be recruited into the trial, including 1,000 people from nine sites in the UK.

Sir Mene Panaglos, executive vice president of biopharmaceutical research and development at AstraZeneca, said: “There is going to be a significant number of people - even in a world where vaccines are highly effective - who will not respond to vaccines, or in fact will not take vaccines.

“So having monoclonal antibodies as potential therapeutics is also important.”

He called for people, especially vulnerable people over the age of 60 who are immuno-suppressed, to sign up to the trial. These will include people from health care and care home settings.

The UK Government agreed in principle to secure access to one million doses of the antibody treatment, dubbed AZD7442, if it produces successful results in the phase three trials.

Kate Bingham, chairwoman of the UK’s Vaccine Taskforce, said the treatment will be part of the UK’s Covid protection portfolio.

“So, obviously, vaccines work in people who have a functional immune system,” she said. “[But] if you are immuno-suppressed, and you are going through bone marrow transplants, or indications or treatments that actually reduce your ability to mount an immune response, then this is basically the only current way of providing that short-term passive immunity.

“So we are absolutely looking to protect those people who are immuno-suppressed or those people who need immediate protection, because you will remember that vaccines typically take about six weeks to work.”

The NHS Vaccine Research Registry, which comprises a list of 340,000 volunteers willing to take part in clinical trials, will provide some patients for AstraZeneca’s trial.

Sir Mene explained that the two antibodies have been engineered with a life-extension technology to make them effective for longer.

Scientists think the combination will provide protection for at least six months, but closer to 12 months. He described it as a “passive vaccination”.

It is unclear how much the treatment will cost, but Sir Mene said it will be “more expensive than vaccines”, adding: “We hope to make it cost-effective.”

Alok Sharma, the business aecretary, said in a statement: “I am very proud that the UK is the first country in the world to begin this invaluable study, and that a fifth of trial volunteers will be from Britain - a testament to our fantastic life sciences sector and the willingness of our people to come forward to help others.

“As we move closer to a Covid-19 vaccine, we must keep driving forward clinical trials for new and alternative treatments that protect our vulnerable, particularly those who cannot receive a vaccine.

“That is why we have procured one million doses of AstraZeneca’s long-acting antibody treatment if it meets robust safety and effectiveness standards.”
Newsletter

Related Articles

0:00
0:00
Close
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
William and Kate Are Moving House – and the New Neighbors Were Evicted
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
Taylor Swift on the Way to the Super Bowl? All the Clues Stirring Up Fans
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Apple Expands Social Media Presence in China With RedNote Account Ahead of iPhone 17 Launch
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Bill Barr Testifies No Evidence Implicated Trump in Epstein Case; DOJ Set to Release Records
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
Emails Worth Billions: How Airlines Generate Huge Profits
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
JPMorgan Plans New Canary Wharf Tower
Zelenskyy and his allies say they will press Trump on security guarantees
Beijing is moving into gold and other assets, diversifying away from the dollar
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
The Drought in Britain and the Strange Request from the Government to Delete Old Emails
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
"No, Thanks": The Mathematical Genius Who Turned Down 1.5 Billion Dollars from Zuckerberg
The surprising hero, the ugly incident, and the criticism despite victory: "Liverpool’s defense exposed in full"
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
Jellyfish Swarm Triggers Shutdown at Gravelines Nuclear Power Station in Northern France
×